Evogene (EVGN) director Sarit Firon details long-dated stock option grants
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Evogene Ltd. director Sarit Firon filed an initial Form 3 disclosing stock option holdings in the company. The filing lists multiple stock option grants over ordinary shares with exercise prices ranging from 1.2900 to 70.5500 per share and expiration dates between 2026 and 2035. One grant for options over 2,500 ordinary shares at an exercise price of 1.2900 vests in equal quarterly installments of 25%, becoming fully vested on the one-year anniversary of the August 18, 2025 grant date.
Positive
- None.
Negative
- None.
Insider Trade Summary
10 transactions reported
Mixed
10 txns
Insider
Firon Sarit
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy ordinary shares) — 1,000 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What does Evogene (EVGN) disclose in Sarit Firon’s Form 3 filing?
The Form 3 filing shows director Sarit Firon reporting holdings of multiple stock options over Evogene ordinary shares, with specified exercise prices and expiration dates. It establishes Firon’s initial derivative ownership position as a company insider without indicating any recent purchases or sales.
What stock option grants are reported for Evogene (EVGN) director Sarit Firon?
Sarit Firon reports several stock option grants over Evogene ordinary shares with exercise prices from 1.2900 to 70.5500 per share. The options have expiration dates ranging from 2026 through 2035, reflecting a staggered series of long-dated equity incentives.
How do the lowest-priced Evogene (EVGN) options held by Sarit Firon vest?
The options with a 1.2900 exercise price over 2,500 ordinary shares vest quarterly, at 25% per quarter. They become fully vested on the one-year anniversary of the August 18, 2025 grant date, according to the Form 3 footnote.
Does Sarit Firon’s Evogene (EVGN) Form 3 show any stock purchases or sales?
No explicit buy or sell transactions appear in the data provided. The entries are categorized as holdings of stock options, with transaction codes marked as unknown and no transaction shares reported, indicating disclosure of existing positions rather than new trades.
What is the time span of Evogene (EVGN) option expirations reported for Sarit Firon?
The reported stock options over Evogene ordinary shares have expiration dates ranging from August 10, 2026 to August 18, 2035. This shows Firon’s equity incentives extend across nearly a decade, covering multiple grant years and strike prices.